Dr. Ghorra studies the effectiveness of treatments for specific conditions, particularly in patients with thalassaemia who are also dealing with chronic hepatitis C virus (HCV) infection. His research highlights how combining different treatments can lead to better health outcomes for these patients. He also examines how the style of patient care in surgical ICUs can impact recovery and survival rates, investigating the differences between open and closed patient management models. By focusing on these areas, Dr. Ghorra aims to provide clearer treatment paths and improved care for vulnerable patient populations.
Key findings
In a study of thalassaemia patients with chronic hepatitis C, 62.5% of those treated with both peginterferon alpha-2a and ribavirin cleared the virus by 72 weeks, compared to 30% for those on peginterferon alone.
Switching to a closed surgical ICU model resulted in a reduced mortality rate of 6.04%, significantly lower than the 14.4% in the open model.
Complication rates were lower in the closed units, recorded at 44.14%, compared to 55.84% in the open units.
Frequently asked questions
Does Dr. Ghorra study thalassaemia?
Yes, Dr. Ghorra researches treatments for thalassaemia patients, especially those dealing with chronic hepatitis C.
What treatments has Dr. Ghorra researched?
He has studied the effectiveness of peginterferon alpha-2a alone and in combination with ribavirin for chronic hepatitis C in thalassaemia patients.
Is Dr. Ghorra's work relevant to patients in surgical ICUs?
Yes, his research on the management style in surgical ICUs provides important insights into improving patient outcomes and reducing complications.
Publications in plain English
Efficacy and tolerability of peginterferon alpha-2a with or without ribavirin in thalassaemia major patients with chronic hepatitis C virus infection.
2005
British journal of haematology
Inati A, Taher A, Ghorra S, Koussa S, Taha M +2 more
Plain English This study looked at how well a treatment combining peginterferon alpha-2a and ribavirin works for thalassaemia patients with chronic hepatitis C. Among the 20 patients treated, 30% who received only peginterferon and 62.5% who got both treatments cleared the virus by 72 weeks. The findings are important because they show that adding ribavirin improves treatment effectiveness for some patients, although it also increased their need for blood transfusions by 34%.
Who this helps: Thalassaemia patients with chronic hepatitis C and their healthcare providers.
Analysis of the effect of conversion from open to closed surgical intensive care unit.
1999
Annals of surgery
Ghorra S, Reinert SE, Cioffi W, Buczko G, Simms HH
Plain English The study looked at how patient outcomes changed when a surgical intensive care unit (ICU) switched from an open model, where private doctors managed their patients, to a closed model, where a specialized team of doctors handled all patient care. They found that the closed unit had a significantly lower mortality rate of 6.04% compared to 14.4% in the open unit, and fewer complications occurred, with rates of 44.14% in the closed unit versus 55.84% in the open unit. This is important because it suggests that having a dedicated team of certified doctors managing the ICU leads to better health outcomes for patients.
Who this helps: This helps patients in surgical ICUs and their families.